Management for Pharmaceutical Chargebacks
Gain better control of pharmaceutical chargebacks through unparalleled chargeback data processing and analytics
Data retrieval, scrubbing, validation and reconciliation, at scale, is a daunting challenge for most companies, and becomes even more critical for high priced products.
Effective data management for pharma chargebacks can uncover up to 10-15% gross margin erosion based on the trade partner mix, commercial contract volume, discount levels, and DSA terms
Gain Better Control of Pharmaceutical Chargebacks
Achieve contracting excellence by choosing a partner that has regulatory processes and compliance standards, including but not limited to pharmaceutical chargebacks.
With IntegriChain’s Chargeback Management BPaaS (Business Process as a Service), we offer a full suite of pharmaceutical chargeback data reconciliation and analytics services across Commercial and Government contracts such as GPO/IDN providers, 340B, and FSS. Our contracts and pricing services combine expert contract management with unparalleled chargeback data verification. By applying comprehensive validity checks and delivering operational reporting and wholesaler scorecards, we are able to achieve more accurate data for pharma chargeback management.
ICyte: Built for Pharma Chargeback Management Usability and Productivity
For a number of reasons, pharmaceutical manufacturers are regularly forced to spend system and human resources on identifying and resolving errors with pharmaceutical chargebacks. Clearly, wholesaler distribution faces severe margin pressure. Further, widening gaps between 340B contract price and WAC incentivize arbitrage behavior, and trade partners don’t report reversals on salable returns to inventory up to 90 days after the original sale. In all cases, errors with pharmaceutical chargebacks are difficult to prove without sophisticated analytics, experienced staff, and a robust application for identifying errors
ICyte Chargeback Application provides:
- Validations and HDA Error Processing Reconciliation
- Resubmission Processing
- Parent/child Membership Management for Wholesalers and Payers
- Full EDI 844, 845, and 849 capabilities
- Wholesaler Scorecards
- ERP Integration
Read our ICyte Platform: Pharma Market Access Software page for additional information on ICyte.
Interested in learning more?
Blog
Perspectives on Pharma Market Access Launch & Challenges: Part 2
Commercialization is a critical process for any pharmaceutical manufacturer, with alignment of multiple work streams that span across market access and brand teams as well as finance and the c-suite. We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
Blog
May Market Update
Updates on US Territory Enrollment Updates, Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and its Relevance to FSS Agreements, and State Price Transparency Reporting Updates.